康芝药业
(300086)
| 流通市值：19.84亿 | | | 总市值：20.48亿 |
| 流通股本：4.41亿 | | | 总股本：4.55亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 363,813,064.07 | 220,198,812.69 | 104,742,326.3 | 739,569,815.25 |
| 营业收入 | 363,813,064.07 | 220,198,812.69 | 104,742,326.3 | 739,569,815.25 |
| 二、营业总成本 | 522,876,726.08 | 342,586,586.75 | 153,590,745.48 | 705,188,764.18 |
| 营业成本 | 169,332,084.33 | 95,548,126.84 | 49,746,165.33 | 295,773,602.18 |
| 税金及附加 | 9,558,031.15 | 6,070,570 | 2,994,628.84 | 15,606,695.98 |
| 销售费用 | 209,495,211.71 | 151,027,580.6 | 60,621,744.14 | 212,909,827.75 |
| 管理费用 | 96,524,579.43 | 64,901,252.2 | 31,166,799.58 | 139,676,131.1 |
| 研发费用 | 23,051,939.62 | 15,389,443.42 | 4,640,407.51 | 18,679,648.77 |
| 财务费用 | 14,914,879.84 | 9,649,613.69 | 4,421,000.08 | 22,542,858.4 |
| 其中:利息费用 | 13,890,583.08 | 9,015,682.99 | 4,142,784.49 | 25,295,163.28 |
| 其中:利息收入 | 692,595.9 | 569,597.85 | 328,492.61 | 2,855,312 |
| 加:公允价值变动收益 | - | - | - | -11,600,532.3 |
| 加:投资收益 | 16,845,077.62 | - | - | - |
| 资产处置收益 | 25,148.38 | 25,148.38 | - | 717,537.53 |
| 资产减值损失(新) | -10,116,157.64 | -5,968,619.81 | 1,457,450.62 | -4,512,626.59 |
| 信用减值损失(新) | 3,394,478.94 | 4,209,201.71 | -1,177,807.81 | -3,571,850.14 |
| 其他收益 | 8,353,418.62 | 7,460,166.65 | 929,329.73 | 9,569,765.66 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -140,561,696.09 | -116,661,877.13 | -47,639,446.64 | 24,983,345.23 |
| 加:营业外收入 | 594,634.67 | 158,132.81 | 5,660.97 | 133,268.72 |
| 减:营业外支出 | 1,944,447.71 | 1,390,639.79 | 230,196.22 | 1,670,837.07 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -141,911,509.13 | -117,894,384.11 | -47,863,981.89 | 23,445,776.88 |
| 减:所得税费用 | -17,259,985.95 | -15,766,883.96 | -529,903.56 | 18,277,109.63 |
| 六、净利润 | -124,651,523.18 | -102,127,500.15 | -47,334,078.33 | 5,168,667.25 |
| 持续经营净利润 | -124,651,523.18 | -102,127,500.15 | -47,334,078.33 | 5,168,667.25 |
| 归属于母公司股东的净利润 | -122,730,788.69 | -100,863,188.44 | -46,504,959.09 | 11,529,863.15 |
| 少数股东损益 | -1,920,734.49 | -1,264,311.71 | -829,119.24 | -6,361,195.9 |
| (一)基本每股收益 | -0.27 | -0.22 | -0.1 | 0.03 |
| (二)稀释每股收益 | -0.27 | -0.22 | -0.1 | 0.03 |
| 八、其他综合收益 | - | - | - | -484,823.53 |
| 归属于母公司股东的其他综合收益 | - | - | - | -484,823.53 |
| 九、综合收益总额 | -124,651,523.18 | -102,127,500.15 | -47,334,078.33 | 4,683,843.72 |
| 归属于母公司股东的综合收益总额 | -122,730,788.69 | -100,863,188.44 | -46,504,959.09 | 11,045,039.62 |
| 归属于少数股东的综合收益总额 | -1,920,734.49 | -1,264,311.71 | -829,119.24 | -6,361,195.9 |
| 公告日期 | 2024-10-30 | 2024-08-27 | 2024-04-29 | 2024-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |